Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Fusidic acid - topical

Classification: B

Drug products: Fucidin, Fucidin®, Fucidin®-Hydrocortison, Fucidine, Fucidin-Hydrocortison, Fucithalmic, Fucithalmic®, Fusidinsyra/Betametason Ebb, Fusidinsyra/Betametason LEO, Fusidinsyra/Hydrokortison 2care4

ATC code: D06AX01, D07CA01, D07CC01, S01AA13

Summary

No studies with a clinically relevant sex analysis regarding the pharmacokinetics of fusidic acid have been found.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of fusidic acid have been found.

Effects

No studies with a clinically relevant sex analysis regarding the effects of fusidic acid have been found.

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of fusidic acid have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2015-10-21

References

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk
Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Authors: Maria Enghag, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson